Article Information
History
- May 18, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Noyuri Yamaji, M.N.Sc., R.N.1,2,
- Sachiko Ohde, PhD, EdM1,3,
- Kimi Estela Kobayashi-Cuya, PhD1,
- Shota Saito, PhD1 and
- Osamu Takahashi, MD MPH PhD1,3,4,*
- 1Center for Clinical Epidemiology and Health Technology Assessment, St. Luke’s International University, Chuo-ku, Japan
- 2Global Health Nursing, St. Luke’s International University, Chuo-ku, Japan
- 3St. Luke’s International University Graduate School of Public Health, Chuo-ku, Japan
- 4Department of General Internal Medicine, St. Luke’s International Hospital, Chuo-ku, Japan
- ↵*Corresponding author:
Osamu Takahashi, OMURA Susumu & Mieko Memorial, St. Luke’s Center for Clinical Academia, 5th Floor, 3-6-2, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan, Telephone: +81-3-5550-4101, E-mail: otakahas{at}slcn.ac.jp
Posted May 18, 2020.
Current Evidence of the Pharmacological Treatments for Novel Coronavirus Disease 2019 (COVID-19): A Scoping Review
